Желудочно-кишечные
Инфаркт или резекция кишки (ниже двенадцатиперстной кишки), селезёнки, печени или жёлчного пузыря, когда-либо, по любым причинам (счёт 2, если более, чем в одном месте) Мезентериальная недостаточность Хронический перитонит
Стриктуры или хирургические операции на верхней части ЖКТ, когда-либо
Мышечно-скелетные Мышечная атрофия или слабость
Деформирующий или арозивный артрит (включая вправимые деформации, исключая аваскулярные некрозы) Остеопороз с переломами или коллапсом позвонков (исключая аваскулярный некроз) Аваскуляриый некроз (счёт 2, если >1) Остеомиелит
Кожные
Рубцующаяся хроническая алопеция Обширное рубцевание или панникулит (кроме скальпа и подушечек пальцев)
1(2)
1(2)
1(2)
1(2)
160 ♦ Ревматология ♦ Системная красная волчанка
Окончание табл. 3
|
|
| | Изъязвление кожи (исключая тромбоз) в течение более 6 мес Преждевременная недостаточность гонад Сахарныйдиабет (вне зависимости от терапии) Малигнизация(исключая дисплазию) (счёт 2, если более одной локализации)
| 1 1 1 1(2)
|
 ЛИТЕРАТУРА
\.Abu-ShakraM., UrowitzM.B., Gladman D.D., GoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center//J. Rheumatol. - 1995. - Vol. 22. -P. 1265-1270.
I.Abu-ShakraM., UrowitzM.B., Gladman D.D., GoughJ. Mortality studies in systemic lupus erythematosus. Results from a single center//Ibid. - P. 1259-1264. 3. Al-Herz A., Schulzer M., Esdaile J.M. Survey of antimalarial use in lupus pregnancy and lactation // Ibid. - 2002. - Vol. 29. -P. 700.
4. Alarcon-SegoviaD., TumlinJ.,FurieR.A. et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double blind, placebo controlled study // Arthritis Rheumatol. - 2003. - Vol. 48, N 2. -P. 442-454.
5. Alvarez-Nemegyei J., Cobarrubias-Co-
bos A., Escalante-Triay F. et al. Bromo-
criptine in systemic lupus erythematosus: a
double-blind, randomized, placebo-cont
rolled study // Lupus. - 1998. - Vol. 7. -
P. 414-419.
6. Appel A.E., Sablay L.B., Golden R.A. et
al. The effect of normalization of serum
complement and anti-DNA antibody on the
course of lupus nephritis // Am. J. Med. -
1978. -Vol.64. - P. 274-283.
7. Austin H.A., Klippel J.K., Balow J.E. et
al. Therapy of lupus nephritis // N. Engl. J.
Med. - 1986. - Vol. 314. - P. 614-619.
8. Austin H.A., Vaugham EM., Boumpas
D.T. et al. Lupus membranous nephropathy:
Controlled trial of prednisone, pulse cyclo-
phosphamide and cyclosporine (abstract) //
J. Am. Soc. Nephrol. - 2000. - Vol. 11.-P. A439.
9. Baletta M., Sabella D., Magri P. et al.
Cyclosporin plus steroids versus steroids
alone in the treatment of lupus nephritis / Eds
Sessa, Meroni, Battini // Contrib. Nephrol.
- 1992. - Vol. 99. - R 129-136.
10. Bansal V.K., BeioJ.A. Treatment of lupus
nephritis, a meta-analysis of clinical trials//
Am. J. Kidney Dis. - 1997. - Vol. 29. -
R 193-199.
11. Barile L., Olguin L., Ariza R. et al.
Controlled clinical trial of cyclophosphamide
vs methylprednisolone in severe neurologic
manifestation in SLE // Arthritis Rheum
(Abstracts). -2001. -Vol.88.
12. Barile L.A., Jara L.J., Medina-
Rodriguez F. et al. Pulmonary haemorrhage
in systemic lupus erythematosus // Lupus.
- 1997. -Vol.6. -P. 445-448.
13. Barile L, Lavatle С Transverse myelitis
in systemic lupus erythematosus. The effect
of IV pulse methylprednisolone and cyc
lophosphamide//J. Rheumatol. - 1992. -
Vol. 19. - R 370.
14. Ben-CheritE., Putterman C.Naparstek
У. Lupus refractory pleural effusion: transient
reasons to intravenous immunoglobulins //
Ibid. - 1991. - Vol. 18. - P. 1635-1637.
15. Bermas B.L, Hill J.A. Effects of immu-
nosuppressive drugs during pregnancy //
Arthritis Rheum. - 1995. - Vol. 38. -
R 1722.
16. Blanchetle V., Freedman J., Garvey B.
Management of chronic immune thrombo-
cytopenic purpura in children and adults //
Semin. Hematol. - 1998. - Vol. 35. -
Suppl. 1. - P. 36.
17. Boehm I.В., Boehm G.A., Bauer R.
Management of cutaneous lupus erythe-
 matosus with low dose methotrexate: indication for modulation of inflammatory mechanisms // Rheumatol. Int. — 1998. — Vol. 18. - P. 59-62.
18. BoletisJ.N., loannidisJ.P.A., Boki K.A.,
Moutsopoulos H.M. Intravenous immuno-
globulin compared with cyclophosphamide
for proliferative lupus nephritis // Lancet. —
1999. - Vol. 354. - P. 569-570.
19. Bootsma H., Spronik P., Derksen R. et
al. Prevention of relapses in systemic lupus
erythematosus//Ibid. - 1995. - Vol. 345.
- P. 1595-1599.
20. Boumpas D.T., Barez S., Klippel J.H.,
Balow J.E. Intermittent cyclophosphamide
for the treatment of autoimmune thrombo-
cytopenia in systemic lupus erythematosus
//Ann. Intern. Med. - 1990. - Vol. 112.-
P. 674.
21. Boumpas D.T., Austin H.A., Vaughn
EM. et al. Controlled trial of pulse methyl-
prednisolone versus two regimens of pulse
cyclophosphamide in severe lupus nephritis
// Lancet. - 1992. - Vol. 340. - P. 741-
745.
22. BoumpasD.T., FesslerB.J., Austin H.A.
Ill et al. Systemic lupus erythematosus:
EmergingconceptsPart2: Dermatologicand
joint disease, the antiphospholipid antibody
syndrome, pregnancy and hormonal therapy,
morbidity and mortality, and pathogenesis //
Ann. Intern. Med. - 1995. - Vol. 123. -
P. 42.
23. Boumpas D.T., Patronas N.J., Dalakas
M.C. et al. Acute transverse myelitis in
systemic lupus erythematosus: Magnetic
resonance imaging and review of the lite
rature//J. Rheumatol. - 1990. - Vol. 17. -
P. 89.
24. Boumpas D.T., Yamada H., Patronas
N.J. et al. Pulse cyclophosphamide for severe
neuropsychiatric lupus // Q. J. Med. —
1991. - Vol. 81, N 296. - P. 975-984.
25. Buchanan N.M.M., Toubi E..
Khamashta M.A. et al. Hydroxychloroquine
and lupus pregnancy: review of a series of 36
cases // Ann. Rheum. Dis. - 1996. -
Vol. 55. - P. 486-488.
26. Cade R., Spooner G., Schlein E. et al.
Comparison of azathioprine, prednisone, and
Системная красная волчанка о 161
heparin alone or combined in treating lupus nephritis//Nephron. - 1973. - Vol. 10. -R 37-56.
27. Callen J.P., Spencer L.V., Bhatnagar
Burruss J. et al. Azathioprine: an effective,
corticosteroid-sparing therapy for patients
with recalcitrant cutaneous lupus erythe
matosus or with recalcitrant cutaneous
leukocytoclastic vasculitis // Arch. Der-
matol. - 1991. - Vol. 127. - P. 515-522.
28. Callen J.P. Treatment of cutaneous le
sions in patients with lupus erythematosus //
Dermatol. Clin. - 1994. - Vol. 12. -
P. 201-206.
29. Carette S., Klippel J.H. Decker J.L. et al.
Controlled studies of role immunosuppres-
sive drugs in lupus nephritis // Ann. Intern.
Med. - 1983. - Vol. 99. - R 1 -8.
30. Carneiro J.R.M., Sato E. Double blind,
randomized, placebo controlled clinical trial
of methotrexate in systemic lupus erythe
matosus // J. Rheumatol. — 1999. —
Vol.26. - R 1275-1279.
31. Cervera R., Khamashita M.A., Font J.
et al. Morbidity and mortality in systemic
lupus erythematosus during a 5-year peri
od // Medicine. - 1990. - Vol. 78. -
R 167-175.
32. Chan T.M., Li F.K., Hao W.K. et al.
Treatment of membranous lupus nephritis
with nephrotic syndrome by sequential
immunosuppression // Lupus. — 1999. —
Vol.8. -R 545-551.
33. Chan T.M., Li F.K., Tang C.S.O. et al.
Efficacy of mycophenolate mofetil in patients
with diffuse proliferalive lupus nephritis //
N. Engl. J. Med. - 2000. - Vol. 343. -
R 1156-1162.
M.ChangD.M.,LanJ.L.,LinH.Y.,LuoS.F. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial // Arthritis Rheum. - 2002. - Vol. 46. -R 2942-2947.
35. Contreras G., Pardo V., Leclercq B. et al. Maintenance therapy for proliferative form of lupus nephritis: a randomized clinical trial comparing quarterly intravenous cyclophosphamide versus oral mycophenolate mofetil
162 ♦ Ревматология ♦ Системная красная волчанка
 or azathioprine (abstract) // J. Am. Soc. Nephrol. - 2002. - Vol. 13. - P. 15 A.
36. Corley C.CJr, LessnerH.E., Larsen W.E.
Azathioprine therapy of «autoimmune»
diseases//Am. J. Med. - 1966. -Vol.41. -
P. 404.
37. Costedoat-Chalumeau N., Amoura Z.,
Aymard G. et al. Evidence of transplacental
passage of hydroxychloroquine in humans //
Arthritis Rheum. - 2002. - Vol. 46. -
P. 1123-1124.
38. CoulB.M., Williams L.S., Goldstein LB.
et al. Anticoagulants and antiplatelet agents
in acute ischemic stroke. Report of the
joint stroke guideline develkpment com
mittee of the American Academy of Neu
rology and the American Stroke Association
(a Division of the American Heart Asso
ciations)// Stroke. - 2002. - Vol. 33. - P.
1934-1942.
39. Cuadrado M.J. Treatment and monito
ring of patients with antiphospholipid antibo
dies and thrombotic history (Hughes synd
rome)// Curr. Rheumatol. Rep. - 2002. -
Vol. 4. - P. 392.
40. D'Cruz D. Antimalarial therapy: a pa
nacea for mild lupus? // Lupus. - 2001. -
Vol. 10.-P. 148-151.
41. D'Cruz D., Khamashta M., Hughes G.
Pulmonary manifestations of systemic lupus
erythematosus // Dubois' Lupus Erythema-
tosus. - 2002. - P. 663-683.
42. Derksen R.H.W.M., Hene R.J.,
Kallenberg C.G.M. et al. Prospective multi-
center trial on the short term effect of plasma
exchange versus cytotoxic drugs in steroid
resistant lupus nephritis // Neth. J. Med. -
1988.-Vol.33.-P. 168-177.
43. Derksen H.W.M., Khamashta M.A.,
Branch D.W. Management of the obstetric
antiphospholipid syndrome // Arthritis
Rheum. - 2004. - Vol. 50. - P. 1028-1039.
44. Dinanat H.J., Decker J.L., Klippel J.H.
et al. Alternative modes of cyclophosphami-
de and azathioprine therapy in lupus
nephritis//Ann. Intern. Med. - 1982. -
Vol. 96. - R 728-736.
45. Donadio J.V., Holley K.E., Wagoner
R.D. et al. Further observation on the treat
ment of lupus nephritis with prednisone and
combined prednisone and azathioprine // Arthritis Rheum. - 1974. - Vol. 17. -R 573-581.
46. Donadio J.V., Holley K.E., Ferguson
R.H., llstrup D.M. Treatment of diffuse
proliferative lupus nephritis with prednisone
and combined prednisone and cydophos-
phamide // N. Engl. J. Med. - 1978. -
Vol.299.-P. 1151-1155.
47. Donadio J.V., Holley K.E., Wagoner
R.D. et al. Treatment of lupus nephritis with
prednisone and combined prednisone and
azathioprine //Ann. Intern. Med. — 1972.
- Vol. 77. - R 829-835.
48. Dooley M.A., Cosio F.G., Nachman P.
et al. Mycophenolate mofetil therapy in lu
pus nephritis: Clinical observations //
J. Am. Soc. Nephrol. - 1999. - Vol. 10. -
R833.
49. Dubois EL. Letter: Ibuprofen for sys
temic lupus erythematosus // N. Engl. J.
Med. - 1975. - Vol. 293. - P. 779.
50. EulerH.H., SchroederJ.O., Harten P. et
al. Treatment-free remission in severe sys
temic lupus erythematosus following syn
chronization of plasmapheresis with sub
sequent pulse cyclophosphamide// Arthritis
Rheum. - 1994. - Vol. 37. - P. 1784.
51. Felson D. T., Anderson J. Evidence for the
superiority of immunosuppressive drugs and
prednisone over prednisone alone in lupus
nephritis//N. Engl. J. Med. - 1984. -Vol.
311. -P. 1528-1533.
52. Flanc R.S., Roberts M.A., Strippoli
G.F.M. et al. Treatment for lupus nephri
tis //The Cochrane Library. - 2004. - Is. 2.
53. Fleming H.G. et al. Bullous systemic
lupus erythematosus // Int. J. Dermatol. —
1989. -Vol.28. - P. 321-326.
54. Fu L.W., YangLY., Chen W.P., Lin C.Y.
Clinical efficacy of cyclosporin A neoral in the
treatment of pediatric lupus nephritis with
heavy proteinuria // Br. J. Rheumatol. -
1998:.-Vol. 37. -P. 217-221.
55. Fucuda M., Kamiyama Y., Kawahara K.
et al. The favorable effect of cyclophos
phamide pulse therapy in the treatment of
massive pulmonary haemorrhage in systemic
lupus erythematosus // Eur. J. Paediatr. —
1994. -Vol. 153. - P. 167-170.
56.  Galindo-Rodriguez G., Avlna-Zubieta
J.A., Pizarro S. et al. Cyclophosphamide
pilse therapy in optic neuritis due to systemic
lupus erythematosus: an open trial //Am. J.
Med. - 1999. - Vol. 106, N 1. - P. 65-69.
57. George J.N., WoolfS.H., Raskob G.E. et
al. Idiopathic thrombocytopenic purpura: A
practice guideline developed by explicit
methods for the American Society of Hema-
tology// Blood. - 1996. - Vol. 88. - P. 3.
58. GinsbergJ.S., WeltsP.S.. Brill-Edwards
P. et at. Antiphospholipid antibodies and
venous thromboembolism // Ibid. - 1995.
- Vol. 86. - P. 3685.
59. Glicklich D., AcharyaA. Mycophenolate
mofetil therapy for lupus nephritis refractory
to intravenous cyclophosphamide // Am. J.
Kidney Dis. - 1998. - Vol. 32. - P. 318.
60. Ginzler E., Diamond H., Guttadauria
M., Kaplan D. Prednisone and azathioprine
compared to prednisone plus low dose azathi-
oprine and cyclophosphamide in the treat
ment of diffuse lupus nephritis // Arthritis
Rheum. - 1976. - Vol. 19. - P. 693-699.
61. GoebelK.M., Gassel W.D., Goebel F.D.
Evaluation of azathioprine in autoimmune
thrombocytopenia and lupus erythematosus
// Scand. J. Haematol. - 1973. - Vol. 10.
- P. 28.
62. Goldstein £., Carey W. Discoid lupus
erythematosus: successful treatment with
oral methotrexate // Arch. Dermatol. -
1994. - Vol. 130. - P. 938-939.
63. Gourley M.F., Austin H.A., Scott D. et
al. Methylprednisolone and cyclophos
phamide alone or in combination in patients
with lupus nephritis//Ann. Intern. Med. -
1996.-Vol. 125.-P. 549-557.
64. Hahn B.V., Kantor O.S., Osterland C.K.
Azathioprine plus prednisone compared with
prednisone alone in the treatment of systemic
lupus erythematosus //Ibid. — 1975. —Vol.
83. - R 597-605.
65. Hellmann D.B.. Petri M., Whiting-
O'Keefe Q. Fatal infections in systemic lupus
erythematosus: the role of opportunistic
organisms//Medicine (Baltimore). - 1987.
-Vol.66. -P. 341-348.
66. Hirsh J.. Fuster V., AnsellJ.. Halperin
J.L. American Heart Association/American
Системная красная волчанка о- 163
College of Cardiology Foundation Guide to warfarin therapy // Circulation. - 2003. -Vol. 107. -P. 1692-1711.
67. Hochberg M.C. Updating the American
College of Rheumatology revised criteria for
the classification of systemic lupus erythe
matosus. [Letter] // Arthritis Rheum. -
1997.-Vol.40.-P. 1725.
68. Houssiau F.A., Vasconcetos C., D'Cruz
D. et al. Immunosuppressive therapy in lu
pus nephritis // ibid. - 2002. - Vol. 46. -
P. 2121-2131.
69. Illei G.G., Austin H.A., Crane M. et al.
Combination therapy with pulse cyclo
phosphamide plus pulse methylprednisolone
improves long term renal outcome without
adding toxicity in patients with lupus
nephritis // Ann. Intern. Med. - 2001. -
Vol. 135. - P. 248-2457.
70. Illei G.G.. Takada K., Parkin D. et al.
Renal flares are common in patients with
severe proliferative lupus nephritis treated
with pulse immunosuppressive therapy //
Arthritis Rheum. - 2002. - Vol. 46. -
P. 995-1002.
71. loannou Y., Isenberg D.A. Current
concepts for the management of systemic
lupus erythematosus in adults: a therapeutic
challenge // Postgrad. Med. J. - 2002. -
Vol. 78. - P. 599-606.
72. Jacob H.S. Pulse steroids in hematologic
diseases // Hosp. Pract. (Off. Ed.) - 1985.
- Vol. 20. - P. 87.
73. Jessop S., Whitelaw D., Jordaan F.
Drugs for discoid lupus eryhtematosus //
The Cochrane Library. - 2004. - Is. 2.
74. Kashgarian M. Lupus nephritis:
pathology, pathogenesis, clinical correla
tions, and prognosis // Dubois' Lupus
Erythematosus. - 2002. - P. 1061-1076.
75. Khamashta M.A., Cuadrado M.J.. Mu-
jic F. et al. The management of thrombosis
in the antiphospholipid-antibody syndro
me//N.Engl.J. Med. - 1995.-Vol.332. -
R993.
76. Kolasinski S.L, Chung].В., Albert D.A.
What do we know about lupus membra
nous nephropathy? An analytic review //
Arthritis Care Res. - 2002. - Vol. 47. -
R 450-455.
164 ♦ Ревматология ♦ Системная красная волчанка
77.  Kovacs В., Lafferty T.L., Brent L.H.,
DeHoratius R.J. Transverse myelopathy in
systemic lupus erythematosus: An analysis
of 14 cases and review of the literature //
Ann. Rheum. Dis. - 2000. - Vol. 59. - R 120.
78. Levy Y., Sherer Y., George J. et al.
Intravenous immunoglobulin treatment of
lupus nephritis // Semin. Arthritis Rheum.
- 2000. - Vol. 29. -P. 321.
79. Levy R.A., Vilela V.S., Cataldo M.J. et
al. Hydroxychloroquine (HCQ) in lupus
pregnancy: double-blind and placebo-
controlled study // Lupus. - 2001. - Vol.
10. -P. 401-404.
80. Lewis E.J., Hunsicker L.G., Lan S. et al.
A controlled trial of plasmapharesis therapy
in severe lupus nephritis // N. Engl. J. Med.
- 1992. - Vol. 326. - P. 1373-1379.
81. Liebling M.R., McLaughlin K., Boonsue
S. et al. Monthly pulses of methylpred-
nisolone in SLE nephritis // J. Rheumatol.
- 1982. - Vol. 9. - P. 543-548.
82. Lockshin M.D., Sammarltano L.R.
Lupus pregnancy //Autoimmunity. —2003. —
Vol. 36. - P. 33.
83. Maier W.P., Gordon D.S., Howard R.F.
et al. Intravenous immunoglobulin therapy
in systemic lupus erythematosus-associated
thrombocytopenia // Arthritis Rheum. —
1990. -Vol.33. - P. 1233.
84. Malaviya A.N., Mourou M. Should low-
dose aspirin also be a background therapy for
all patients with systemic lupus erythema
tosus // Lupus. - 2000. - Vol. 9. - P. 561 -
562.
85. Manzi S., Meilahn E.N., Ralrie J.E. et
al. Age specific incidence rates of myocardial
infarction and angina in women with sys
temic lupus erythematosus: comparison with
the Framingham study // Am. J. Epide
miol. - 1997. - Vol. 145. - P. 408-415.
86. Meinao I.M., Sato E., Andrade LE.G.
et al. Controlled trial with chloroquine di-
phosphate in systemic lupus erylhemalosus
//Lupus.- 1996.-Vol. 5.-R 237-241.
87. Mok C.C., Ho C, Siu Y.P. et al.
Treatment of diffuse lupus glomeruloneph-
ritis: a comparison of two cydophos-phamide
containing regimens//Am. J. Kidney Dis. -
2001. -Vol.38. - P. 256-264.
88. Мое C.C., Но СТ., Chan K.W. et al.
Outcome and prognostic indicators of diffuse
proliferative lupus glomerulonephritis treated
with sequential oral cyclophosphamide and
azathioprine//Arthritis Rheum. - 2002. -
Vol.46. -P. 1003.
89. Mok C.C, Ying K.Y., Tang C.W. et al.
Role of azathioprine in the prevention of renal
relapses after successful cyclophosphamide
induction of diffuse proliferative lupus glome
rulonephritis [abstract] // Ibid. - Suppl. -
R S289.
90. Mok C.C, Lau C.S., Chan E.Y., Wong
R.W. Acute transverse myelopathy in
systemic lupus erythematosus: Clinical
presentation, treatment, and outcome //
J. Rheumatol. - 1998. - Vol. 25. - P. 467.
91. Moore P.M., Cupps T.R. Neurological
complications of vasculitis//Ann. Neurol. -
1983. - Vol. 14. - P. 55.
92. Murphy S., LoBuglio A.F. Drug therapy
of autoimmune hemolytic anemia // Semin.
Hematol. - 1976. - Vol. 13. - P. 323.
93. Neuwelt СМ., Lakes S., Kaye B.R. et al.
Role of intravenous cyclophosphamide in the
treatment of severe neuropsychiatric sys
temic lupus erythematosus // Am. J.
Med. - 1995. - Vol. 98. - P. 32.
94. Nossent H.C., Koldingsnes W. Long-
term efficacy of azathioprine treatment for
proliferative lupus nephritis // Rheumatology
(Oxford). - 2000. - Vol. 39. - R 969.
95. Parke A.L. Antimalarial drugs, systemic
lupus erythermatosus and pregnancy //
J. Rheumatol. - 1988. - Vol. 15. - R 607-
610.
96. Parke A.L., West B. Hydroxychloroquine
in pregnant patients with systemic lupus
erythematosus // Ibid. - 1996. - Vol. 23. -
P. 1715-1718.
97. Petri M.A., Lahita B.G., van Vollen-
hoven R.F. et al. Effects of prasterone on
corticosteroid requirement of women with
systemic lupus erythematosus: a double-
blind, randomized, placebo-controlled tri
al // Arthritis Rheum. - 2002. - Vol. 46. -
R 1820-1829.
98. Petersen H.H., Nielsen H., Hansen M.
et al. High dose immunoglobulin therapy in
peroicarditis caused by SLE // Scand.
 J. Rheumatol. - 1990. - Vol. 19. -P. 91-93.
99. Petri M. Mycophenolate mofetil
treatment of SLE // Arthritis Rheum. -
1999. - Vol. 42. - Suppl. - P. S303.
100. Petri M.,AllbrittonJ. Antibiotic allergy
in systemic lupus erythematosus: a case-
control study//J. Rheumatol. - 1992. -
Vol. 19. - P. 265-269.
101. Petri M., Spence D., Bone L.R.,
Hochberg M.C. Coronary artery disease risk
factors in the Johns Hopkins Lupus Cohort:
prevalence, recognition by patients, and
preventive practices // Medicine (Balti
more). - 1992. -Vol.71. -P. 291-302.
102. Pohl M.A., Lan S., Bed T. et al.
Plasmapharesis does not increase the risk for
infection in immunosuppressed patients
with severe lupus nephritis // Ann. Intern.
Med. - 1991. -Vol. 114. - P. 924-929.
103. Quismorio F.P.Jr. Hematologic and
lymphoid abnormalities in systemic lupus
erythematosus // Dubois' Lupus Erythe
matosus. - 2002. - P. 793-819.
104. RadhakrishnanJ., Kunis C.L, D'Agati
V., Appel G.B. Cyclosporine treatment of
lupus membranous nephropathy // Clin.
Nephrol. - 1994. - Vol. 42. - P. 147.
105. Rahman P., Humphrey-Murto S.,
Gladman D.D., Urowitz M.B. Efficacy and
tolerability of methotrexate in antimalarial
resistant lupus arthritis // J. Rheumatol. -
1998.-Vol.25. -R243.
106. Ramos P.C., Mendez M.J., Ames P.R.
et al. Pulse cyclophosphamide in the
treatment of neuropsychiatric systemic lupus
erythematosus // Clin. Exp. Rheumatol. -
1996.-Vol. 14.-P. 295.
107. Rock G.A., Shumack K.H., Buscard
N.A. et al. Canadian Apheresis Study gro
up. Comparison of plasma exchange with
plasma infusion in the treatment of throm-
botic thrombocytopenic purpura // N. Engl.
J. Med. - 1991. - Vol. 325. - P. 393-
397.
108. Rosove M.H., Brewer P.M.
Antiphospholipid thrombosis: Clinical cour
se after the first thrombotic event in 70
patients // Ann. Intern. Med. - 1992. -
Vol. 117. - P. 303.
Системная красная волчанка «■ 165
109. Ruiz-lrastorza G., Khamashta M.A.,
Hughes G.R.V. Antiagregant and
anticoagulant therapy in systemic lupus
erythematosus and Hughes syndrome //
Lupus. - 2001. - Vol. 10. - P. 241-245.
110. RundD., Schaap Т., Gillis S. Intensive
plasmapheresis for severe thrombotic throm
bocytopenic purpura: long-term clinical
outcome // J. Clin. Apheresis. — 1997. -
Vol. 12.-P. 194-195.
111. Sammaritano L. Update on the ma
nagement of the pregnant patients with
antiphospholipid antibody // Curr. Rheu
matol. Rep. - 2001. - Vol. 3. - P. 213-
221.
112. Sanchez-Guerrero J., Karlson E.W.,
Liang M.H. et al. Past use of oral contra
ceptives and the risk of developing systemic
lupus erythematosus // Arthritis Rheum. -
1997.-Vol. 40. -P. 804-808.
113. Sanchez-Guerrero J., Liang M.H.,
Karlson E. W. et al. Postmenopausal estrogen
therapy and the risk for developing systemic
lupus erythematosus // Ann. Intern. Med.
- 1995. - Vol. 122. - R 430-433.
114. Scott J.R., Branch W.D., Kochenour
N.K. Ward K. Intravenous immunoglobulin
treatment of pregnant patients with recurrent
pregnancy loss caused by antiphospho
lipid antibodies and Rh immunization //Am.
J. Obstet. Gynecol. - 1988. - Vol. 159. -
P. 1055.
115. Sesso R., Monteiro M., Sato E. et al. A
controlled trial of pulse cyclophosphamide
versus pulse methylprednisolone in severe
lupus nephritis // Lupus. - 1994. - Vol. 3.
-R 107-112.
116. Schnabel A., Reuter M., Gross W.L.
Intravenous pulse cyclophosphamide in the
treatment of intersticial lung disease due to
collagen vasculardiseases//Arthritis Rheum.
- 1998. - Vol. 41. - R 1215-1220.
117. SimmsR.W., AndersonJJ., ZebriniA.,
Felson D.T. Treatment of glucocorticoid-
induced osteoporosis: a meta-analysis
[Absract] // Ibid. - 1993. - Vol. 36. N 9. -
Suppl. - P. S50.
118. Spinnato J.A., Clark A.L., Pierangeli
S.S., Harris E.N. Intravenous immuno
globulin therapy for the antiphospholipid
166 о Ревматология о Системная красная волчанка
 syndrome in pregnancy // Am. J. Obstet. Gynecol. - 1995. - Vol. 172. - P. 690.
119. Steinberg A.D., Steinberg S.C. Long
term preservation of renal function in patients
with lupus nephritis receiving treatment that
includes cyclophosphamide versus those
treated with prednisone only // Arthritis
Rheum. - 1991. - Vol. 34. - P. 945-950.
120. Steinberg A.D., Decker J.L A double
blind controlled trial comparing cyclo
phosphamide, azathioprine and placebo in
the treatment of lupus glomerulonephritis
// Ibid. - 1974. - Vol. 17. - P. 923-937.
121. Steinberg A.D., Kaltreider H.B.,
Staples P.J. et al. Cyclophosphamide in
lupus nephritis: a controlled trial // Ann. In
tern. Med. - 1971.-Vol. 75. -R 165-171.
122. Stojanovich L., Stojanovich R., Kos-
tich V., Dzjolich E. Neuropsychiatric lupus
favourable response to low dose i.v.
cyclophosphamide and prednisolone (pilot
study)//Lupus. - 2003. - Vol. 12. - P. 3.
123. Strand V., Gladman D., Isenberg D.
Endpoints: consensus recommendations
from OMERACT IV // Ibid. - 2000. -
Vol. 9. - P. 322-327.
124. Sugiyama M., Ogasawara H., Kane-
ko H. et al. Effect of extremely low dose
cyclosporine treatment on the thrombo-
cytopenia in systemic lupus erythematosus
// Lupus. - 1998. - Vol. 7, N 1. - P. 53-56.
125. Sztejnbok M., Stewart A., Diamond
H., Kaplan D. Azathioprine in the treatment
of systemic lupus erythematosus // Arthritis
Rheum. - 1971. - Vol. 14. - P. 639-645.
126. Tarn L.S., Li E.K., Leung C.B. et al.
Long-term treatment of lupus nephritis with
cyclosporinA//QJM. - 1998. -Vol.91. -
R573.
127. TamE.M., Cohen A.S., Fries J.F. et al.
The 1982 revised criteria for the classification
of systemic lupus erythematosus // Arthritis
Rheum. - 1982. - Vol. 25. - P. 1271-
1277.
128. The Canadian Hydroxychloroguine
Study Group. A randomized study of the
effect of withdrawing hydroxychloroquine
suifate in systemic lupus erythematosus //
N. Engl. J. Med. - 1991. - Vol. 324. -
P. 150-154.
129. The Canadian Hydroxychloroquine
Study Group. A long-term study of
hydroxychloroquine withdrawal on exa
cerbations in systemic lupus erythematosus
// Lupus. - 1998. - Vol. 7. - P. 80-85.
130. Trevisani V.F.M., Castro A.A.,Neto J.F.
et al. Cyclophosphamide versus methyl-
prednisolone for treating neuropsychiatric
involvement in systemic lupus erythematosus
// The Cochrane Library. - 2004. - Is. 2.
131. Uramoto KM., Michet C.J., Thumbo
J. et al. Trends in the incidence and mortality
of systemic lupus erythematosus, 1950—
1992 // Arthritis Rheum. - 1999. -
Vol. 42. - P. 46-50.
132. van Vollennoven R., Engleman E.G.,
McGuire J.L. Dehydroepiandrosterone in
systemic lupus erythematosus results of a
double-blind, placebo-controlled, rando
mized clinical trial // Arthritis Rheum. —
1995. - Vol. 38. - P. 1826-1831.
133. van Vollenhoven R.F., Park J.L.,
Genovese U.C. et al. A double-blind,
placebo-controlled clinical trial of de
hydroepiandrosterone in severe systemic
lupus erythematosus // Lupus. - 1999. -
Vol.8.-P. 181-187.
134. Van Vollenhoven H.F.
Denydroepiandrosterone in systemic lupus
erythematosus // Rheum. Dis. Clin. North
Am. - 2000. - Vol. 26. - P. 349-62.
135. Van Vollenhoven R.F., Elliott £>.,
Powell M. et al. Dehydroepiandrosterone
improves cognitive function in patients with
systemic lupus erythematosus-results of
double blind placebo controlled pilot study//
Arthritis Rheum (Abstracts). — 2001. —
P. 26.
136. Wachl D.G., Bounameaux H., de
Moerloose P., Sarasin F.P. Prophylactic
antithrombotic therapy for patients with sys
temic lupus erythematosus with or without
antiphospholipid antibodies//Arch. Intern.
Med. - 2000. - Vol. 160. - P. 2042-2048.
137. WallaceDJ., GoldfingerD.,Pepkowitz
S.H. et al. Randomized controlled trial of
pulse/synchronization cyclophopsphamide
apheresis for proiiferativ.e lupus nephritis //
J. Clin. Apheresis. - 1998. - Vol. 13. -
P. 163-166.
138.  Wallace D.J. Antimalarial agents and
lupus // Rheum. Dis. Clin. North Am. -
1994.-Vol. 20.-P. 243.
139. Wallace D.J., Hahn B.H., KlippelJ.N.
Clinical and laboratory features of lupus
nephtiris // Dubois' Lupus Erythemato-
sus. -2002. -P. 1077-1091.
140. Weitz J.I. Low-molecular-weight
heparins // N. Engl. J. Med. - 1997. -
Vol. 337. - P. 688-698.
141. Williams H.J., Egger MJ., Singer J.I.
et al. Comparison of hydroxychloroquine
and placebo in the treatment of the arthro-
pathy of mild systemic lupus erythemato-
sus // J. Rheumatol. - 1994. — Vol. 21. —
P. 1457-1462.
142. Wilson K., Abeles M. A 2-year, open
ended trial of methotrexate in systemic lupus
erythematosus // Ibid. - P. 1674.
Системная красная волчанка ♦ 167
143. Yoon K.H. Sufficient evidence to
consider hydroxychloroquine as an adjunct
therapy in antiphospholipid antibody
(Hughes') syndrome // Ibid. - P. 2002.
144. Иванова М.М. Системная красная
волчанка //Диффузные болезни соедини
тельной ткани. - М.: Медицина, 1994. -
С. 231-301.
145. Насонов Е.Л. Антифосфолипидный
синдром. — М.: Литера, 2004.
146. Насонов Е.Л. Противовоспалитель
ная терапия ревматических болезней. -
М.: М-Сити, 1996.
147. Соловьёв С.К. Лечение ревматичес
ких болезней ударными дозами метипреда
(пульс-терапия). - М.: Мик, 1999.
148. Соловьёв С.К. Интенсивная терапия
ревматических болезней. Пособие для вра
чей. -М.: Мик, 2001.
 СИСТЕМНАЯ СКЛЕРОДЕРМИЯ
  Системная склеродермия — аутоиммунное заболевание соединительной ткани, основные клинические признаки которого обусловлены распространёнными нарушениями микроциркуляции, фиброзом кожи и внутренних органов. Системная склеродермия — важнейший представитель склеродермической группы болезней, к которым также относятся ограниченная (очаговая)склеродермия, диффузный эозинофильный фасци-ит, склередема Бушке, мультифокаль-ный фиброз, индуцированные формы склеродермии и псевдосклеродермичес-кие синдромы.
МКБ-10: М34 Системный склероз; М34.0 Прогрессирующий системный склероз; М34.1 Синдром CREST; M34.2 Системный склероз, вызванный лекарственными средствами и химическими соединениями; М34. 8 Другие формы системного склероза.
Аббревиатуры: ССД — системная склеродермия; ИЗЛ — интерстициальное заболевание лёгких.
ЭПИДЕМИОЛОГИЯ11
• Распространённость ССД различает
ся между отдельными географически
ми зонами и этническими группами, в
том числе проживающими в одном ре
гионе.
• Первичная заболеваемость колеблет
ся от 3,7 до 19,0 на 1 млн населения
в год.
• ССД чаще встречается у женщин (со
отношение 5—7 к 1) в возрасте 30—
60 лет.
Профилактика не проводится. Скрининг не проводится.
Дата добавления: 2015-10-20 | Просмотры: 617 | Нарушение авторских прав
|
